These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 34968173)
1. The mRNA Revolution is Coming. Bates M IEEE Pulse; 2021; 12(6):2-5. PubMed ID: 34968173 [TBL] [Abstract][Full Text] [Related]
2. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
3. mRNA Vaccines in the COVID-19 Pandemic and Beyond. Hogan MJ; Pardi N Annu Rev Med; 2022 Jan; 73():17-39. PubMed ID: 34669432 [TBL] [Abstract][Full Text] [Related]
4. Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited]. Jawalagatti V; Kirthika P; Lee JH Front Immunol; 2022; 13():884862. PubMed ID: 35592330 [TBL] [Abstract][Full Text] [Related]
5. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Jain S; Venkataraman A; Wechsler ME; Peppas NA Adv Drug Deliv Rev; 2021 Dec; 179():114000. PubMed ID: 34637846 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacovigilance - mRNA COVID-19 vaccines : current state of knowledge on their adverse effects]. Favre V; Ekobena P; Chtioui H; Rothuizen LE; Livio F; Genton B; Buclin T Rev Med Suisse; 2022 Feb; 18(767):190-197. PubMed ID: 35107895 [TBL] [Abstract][Full Text] [Related]
8. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura. Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144 [TBL] [Abstract][Full Text] [Related]
9. Current Status and Future Perspectives on MRNA Drug Manufacturing. Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565 [TBL] [Abstract][Full Text] [Related]
10. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection. Costanzo M; De Giglio MAR; Roviello GN Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678 [TBL] [Abstract][Full Text] [Related]
11. [What are the differences between the various covid-19 vaccines?]. Ligtenberg AJM; Brand HS Ned Tijdschr Tandheelkd; 2021 Jul; 128(epub ahead of print 2021):. PubMed ID: 34228411 [TBL] [Abstract][Full Text] [Related]
12. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. Nojszewska M; Kalinowska A; Adamczyk-Sowa M; Kułakowska A; Bartosik-Psujek H Neurol Neurochir Pol; 2021; 55(1):8-11. PubMed ID: 33555604 [TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2: Unique Challenges of the Virus and Vaccines. Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900 [TBL] [Abstract][Full Text] [Related]
14. The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology. Ye Z; Harmon J; Ni W; Li Y; Wich D; Xu Q ACS Nano; 2023 Aug; 17(16):15231-15253. PubMed ID: 37535899 [TBL] [Abstract][Full Text] [Related]
15. Time and cost of administering COVID-19 mRNA vaccines in the United States. Yarnoff B; Bodhaine S; Cohen E; Buck PO Hum Vaccin Immunother; 2021 Nov; 17(11):3871-3875. PubMed ID: 34613860 [TBL] [Abstract][Full Text] [Related]
16. Positive aspects of the mRNA platform for SARS-CoV-2 vaccines. Hajissa K; Mussa A Hum Vaccin Immunother; 2021 Aug; 17(8):2445-2447. PubMed ID: 33830862 [TBL] [Abstract][Full Text] [Related]
17. Coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness in asymptomatic healthcare workers. Knobel P; Serra C; Grau S; Ibañez R; Diaz P; Ferrández O; Villar R; Lopez AF; Pujolar N; Horcajada JP; Roman M; Comas M; Sala M; Castells X Infect Control Hosp Epidemiol; 2021 Dec; 42(12):1517-1519. PubMed ID: 34167610 [No Abstract] [Full Text] [Related]
18. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
19. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy. Deng Z; Tian Y; Song J; An G; Yang P Front Immunol; 2022; 13():887125. PubMed ID: 35720301 [TBL] [Abstract][Full Text] [Related]
20. Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration. Vanijcharoenkarn K; Lee FE; Martin L; Shih J; Sexton ME; Kuruvilla ME Clin Infect Dis; 2021 Dec; 73(11):2108-2111. PubMed ID: 33989390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]